Skip to content

Mescaline: all studies

Page 59 of 97: studies 581 to 590 of 965, newest first. Back to the mescaline overview

Research

Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics

Journal of Psychopharmacology July 11, 2025 Aleksander Kwaśny, Patrycja Ciurkowska, Wiesław Jerzy Cubała et al. 6 citations

Background: Although classic psychedelic trials show therapeutic potential, the limited diversity of participants raises concerns about generalizability and safety. Aims: This study assesses the representation of race, ethnicity, and sex in interventional clinical trials of psilocybin and lysergic acid diethylamide (LSD) to evaluate disparities in participant diversity. Methods: We conducted a...

DOI: 10.1177/02698811251353250 (opens in new tab) Psilocybin Ethnic group Generalizability theory Clinical trial +3

Clinical Psychedelic Therapy Research Involving Adolescents: Protocol for a Scoping Review of Intervention Studies

Wellcome Open Research July 8, 2025 Khaleel Rajwani, Melanie Almonte, F. Feroz et al. 2 citations

Background Recent years have seen renewed clinical interest in the therapeutic potential of classical psychedelics, such as psilocybin, LSD, DMT, and mescaline. While modern studies have focused on adult populations, adolescents under 18 are routinely excluded due to regulatory, legal, and ethical challenges. Although there exists observational data and historical studies from 1959 to 1974...

Beyond prohibition: A public health analysis of naturalistic psychedelic use

Journal of Psychedelic Studies July 3, 2025 Mark Haden, Sarah A. Paschall, Birgitta Woods 2 citations

Abstract Psychedelic drug use is experiencing a global resurgence, both in clinical research and community settings. This paper presents a comprehensive public health analysis of the naturalistic use of psychedelics—defined as use outside clinical or research environments. Drawing on a review of 104 peer-reviewed articles, this analysis evaluates the mental, physical, and social outcomes...

DOI: 10.1556/2054.2025.00450 (opens in new tab) Naturalism Public health Criminology Psychoanalysis

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

Medical Science Monitor June 30, 2025 Andrzej Silczuk, Robert Madejek, Tytus Koweszko et al. 4 citations

Psychedelics, derived from the Greek words "psyche" (soul) and "deloun" (revealing), are substances historically and currently considered "soul-revealing". Also termed hallucinogens due to their impact on sensory perception, they are further categorized into hallucinogens, such as lysergic acid diethylamide (LSD), psilocybin, and mescaline; entactogens or empathogens, such as...

DOI: 10.12659/msm.948302 (opens in new tab) Mental health Medline Psychotherapist Intensive care medicine

Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.

Drugs Aging June 24, 2025 Lou Vinarcsik, Charles Smoller, George Grossberg 1 citation

The use of drugs with psychedelic and dissociative effects for the treatment of psychiatric illnesses has become increasingly popular in recent years. However, few trials have been conducted to determine the efficacy of these agents in the specific setting of treatment-resistant major depressive disorder (MDD) in older adults. In this paper, we review notable aspects of treatment-resistant MDD...

DOI: 10.1007/s40266-025-01221-5 (opens in new tab) Innovative approach New avenue Agents Treatment +11

Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.

British Journal of Pharmacology June 22, 2025 Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley et al. 9 citations

Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5-HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5-HT2A receptor ligand bias or signalling efficacy. Here, we investigated 5-HT2A receptor signalling properties of...

DOI: 10.1111/bph.70109 (opens in new tab) Full text (opens in new tab) 5‐ht2a receptor Biased agonism Psychedelic drugs 5-ht2a receptor pharmacology +15

Healing in the Native American Church: Ritual Psychopharmacology and Therapeutic Narrative

June 16, 2025 Joseph D. Calabrese 1 citation

This chapter describes healing practices of the Native American Church (NAC) in terms of indigenous understandings, as well from an anthropologically and clinically informed perspectives. Therapeutic approaches are centered on ritual use of Peyote, a psychedelic cactus, which is seen as a sacred medicine and as an omniscient and morally evaluative guardian spirit. The psychopharmacological...

DOI: 10.1163/9789004729759_014 (opens in new tab) Narrative Psychopharmacology Psychotherapist Psychoanalysis +1

Aesthetic quality of psychedelic experience is linked to insight and psychological outcomes

Frontiers in Psychology May 15, 2025 Jake Hooper, Emily L Gyongyosi, Kent E. Hutchison et al. 5 citations

Introduction The aesthetic qualities of psychedelic experiences have long been documented, but their specific contribution to therapeutic outcomes remains understudied. Aesthetic experiences may facilitate emotional breakthroughs and cognitive shifts, potentially playing a crucial role in the lasting psychological benefits observed following psychedelic use. Methods This cross-sectional study...

DOI: 10.3389/fpsyg.2025.1533055 (opens in new tab) Aesthetic Emotion Insight Psychedelics +4

The Analysis of Hallucinogenic Drugs from Plants and Fungi

May 14, 2025 Michael D. Cole, Lata Gautam, Agatha Grela 1 citation

This chapter introduces drugs derived from plants and fungi including lysergic acid diethylamide (LSD), psilocybin (from ‘magic mushrooms’), N,N-dimethyltryptamine (DMT) and mescaline. Their physical description and chemical identification are described. The use of fluorescence detection for HPLC analysis of drugs and the greater selectivity it offers over UV and diode array detection are...

DOI: 10.1039/9781837673056-00062 (opens in new tab) Hallucinogen Traditional medicine

The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field

Neuroscience & Biobehavioral Reviews May 9, 2025 Rotem Petranker, Benjamin Tsang, Omer A. Syed 3 citations

Microdosing, the repeated use of psychedelic substances at low doses, is growing in popularity among recreational consumers. While this practice is associated with many benefits to mood, well-being and health, research in this area is in its early stages and predominantly centered on human applications. In this narrative review, we synthesize the findings from studies investigating the effects...